Lopes RD, Hong H, Harskamp RE, et al. - Researchers performed a network meta-analysis of randomized controlled trials, to assess the safety and efficacy of different antithrombotic regimens in patients with atrial fibrillation (AF) and coronary artery disease, in particular with acute coronary syndrome and/or percutaneous coronary intervention (PCI). From PubMed, EMBASE, EBSCO, and Cochrane databases, 4 randomized studies (n = 10,026; WOEST, PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS) were included. Less bleeding occurred in relation to treatment with a regimen of non-vitamin K antagonist (VKA) oral anticoagulants [NOACs] plus P2Y₁₂ inhibitor vs VKAs plus dual antiplatelet therapy (DAPT). Less bleeding, including intracranial bleeding, but no significant difference in major adverse cardiovascular events was observed in correlation with using strategies omitting aspirin vs strategies including aspirin. In this study, NOAC plus P2Y₁₂ inhibitor was supported as the favored regimen after percutaneous coronary intervention for these high-risk patients with AF. Generally avoiding a regimen of VKA plus DAPT was recommended.